AstraZeneca has put a lot of resources behind its aging blood thinner Brilinta, hoping to keep the anticoagulant's place in doctors' minds fresh for years to come. With a suite of new data and ...

With a series of late-stage trial readouts in the past few years, AstraZeneca has invested heavily in outcomes R&D for its stalwart clotbuster Brilinta. But there's big problem with that approach, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio AstraZeneca has announced two phase 3b ...

The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca's struggling oral antiplatelet drug. The collaboration is the first stage of "a global ...

(CBS/AP) The FDA has approved the blood thinner Brilinta, and that means there's an alternative to the blockbuster pill Plavix for patients who have clogged arteries associated with a condition known ...

The approval was based on data from the phase 3 THALES trial (N=11,016) that compared treatment with ticagrelor plus aspirin to aspirin alone in preventing new stroke events. The Food and Drug ...

(NYSE: AZN) today introduced a creative education program to support patients taking BRILINTA(ticagrelor). Patients who enroll in the program receive support services across multiple channels to help ...

PhaseBio raised $34 million in its series D round, which will advance its lead assets: a treatment for pulmonary arterial hypertension (PAH) developed in-house and a reversal agent of AstraZeneca’s ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BRILINTA ® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for ...

AstraZeneca plcAZN announced disappointing top-line data from the SOCRATES study on its heart drug Brilinta/Brilique (ticagrelor). The study evaluated the efficacy and safety of Brilinta (90 mg, twice ...

The parade of investigations launched by government agencies into a big drugmaker is often shrugged off, at least by investors, who play wait-and-see since the outcome of such probes can, ...